Overall Score

Revenue Model

TSHA remains a pre-commercial biotech with minimal TTM revenue per share of 0.0149, so the business model is still not yet meaningfully monetized.

Gross margin is high at 84.0%, but the company is still deeply unprofitable with a net profit margin of -27.3% and negative operating cash flow.

Unit Economics

The company shows strong gross margin economics, but operating leverage is not yet present given EBIT margin of -27.4% and operating profit margin of -27.9%.

Free cash flow remains negative at -132.5M TTM, indicating the current model still consumes capital rather than generating it.

Scalability

R&D intensity remains very high at 22.3% of revenue, which is typical for a development-stage biotech but limits near-term scalability.

SG&A is also elevated at 7.1% of revenue, and the company has not yet demonstrated scalable operating leverage.

Moat

The business appears to have some potential moat from proprietary gene therapy assets, but there is no evidence yet of durable commercial advantage from revenue scale.

High gross margin suggests differentiated science, but the lack of commercial traction keeps the moat assessment only moderate.

Capital Efficiency

Return on invested capital is -34.5% and return on equity is -56.2%, showing poor capital efficiency at the current stage.

The balance sheet is liquid with a current ratio of 17.8 and cash per share of 1.23, but capital is still being deployed without positive returns.